Request Services Now

Seminars in Translational Science - November 12, 2021

"Rescuing Toxic Drugs Using SyntheticProteolysis"
Presented by Robert Hromas, MD, FACP
Dean, Joe R and Teresa Lozano Long School of Medicine
Vice President for Medical Affairs 
UT Health San Antonio 

Bcl-xl is a well validated cancer target that is responsible forprotecting many types of cancer cells from apoptosis andchemotherapy. We generated a highly potent and specific Bcl-xlsyntholytic (DT2216) that can selectively induce Bcl-xl proteindegradation in all the cells examined except platelets by targetingBcl-xl to an E3 ligase barely expressed in platelets. DT2216-induced Bcl-xl degradation can selectively kill tumor cells but notnormal cells and platelets. DT2216 has a favorable drug propertyand PK and safety profile, and a broad-spectrum anti-canceractivity in vitro and in xenograft mouse models of humancancers in vivo.

Friday, November 12, 2021 
9:00AM - 10:00AM
For more information on participating in this virtual seminar, please head to